CDLX vs. DH, CCSI, ARQQ, WEAV, BLZE, DSP, BAND, XNET, CRNC, and TLS
Should you be buying Cardlytics stock or one of its competitors? The main competitors of Cardlytics include Definitive Healthcare (DH), Consensus Cloud Solutions (CCSI), Arqit Quantum (ARQQ), Weave Communications (WEAV), Backblaze (BLZE), Viant Technology (DSP), Bandwidth (BAND), Xunlei (XNET), Cerence (CRNC), and Telos (TLS). These companies are all part of the "computer software" industry.
Cardlytics vs. Its Competitors
Cardlytics (NASDAQ:CDLX) and Definitive Healthcare (NASDAQ:DH) are both small-cap computer software companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Cardlytics has higher revenue and earnings than Definitive Healthcare. Definitive Healthcare is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
Cardlytics has a net margin of -68.87% compared to Definitive Healthcare's net margin of -124.43%. Definitive Healthcare's return on equity of 3.94% beat Cardlytics' return on equity.
Cardlytics currently has a consensus target price of $2.25, suggesting a potential downside of 1.32%. Definitive Healthcare has a consensus target price of $4.28, suggesting a potential upside of 34.17%. Given Definitive Healthcare's higher probable upside, analysts plainly believe Definitive Healthcare is more favorable than Cardlytics.
68.1% of Cardlytics shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 4.4% of Cardlytics shares are held by company insiders. Comparatively, 14.8% of Definitive Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Cardlytics had 11 more articles in the media than Definitive Healthcare. MarketBeat recorded 13 mentions for Cardlytics and 2 mentions for Definitive Healthcare. Definitive Healthcare's average media sentiment score of 0.45 beat Cardlytics' score of 0.28 indicating that Definitive Healthcare is being referred to more favorably in the news media.
Cardlytics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Summary
Definitive Healthcare beats Cardlytics on 10 of the 17 factors compared between the two stocks.
Get Cardlytics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CDLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardlytics Competitors List
Related Companies and Tools
This page (NASDAQ:CDLX) was last updated on 10/7/2025 by MarketBeat.com Staff
